Pharmacokinetics, Biotransformation, and Excretion of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer Intravenous Dose in Patients with Chronic Kidney Disease on Hemodialysis by Raju Subramanian et al.
ORIGINAL RESEARCH ARTICLE
Pharmacokinetics, Biotransformation, and Excretion
of [14C]Etelcalcetide (AMG 416) Following a Single Microtracer
Intravenous Dose in Patients with Chronic Kidney Disease
on Hemodialysis
Raju Subramanian1,2 • Xiaochun Zhu1 • M. Benjamin Hock1 • Bethlyn J. Sloey1 •
Benjamin Wu1 • Sarah F. Wilson1 • Ogo Egbuna1 • J. Greg Slatter1 •
Jim Xiao1 • Gary L. Skiles1
Published online: 12 August 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Etelcalcetide (AMG 416) is a novel synthetic
peptide calcium-sensing receptor activator in clinical devel-
opment as an intravenous calcimimetic for the treatment of
secondary hyperparathyroidism in patients with chronic kid-
ney disease (CKD) on hemodialysis. Etelcalcetide is com-
posed of seven D-aminoacids with an L-cysteine linked to a
D-cysteine by a disulfide bond. A single intravenous dose of
[14C]etelcalcetide (10 mg; 26.3 kBq; 710 nCi) was adminis-
tered to patients with CKD on hemodialysis to elucidate the
pharmacokinetics, biotransformation, and excretion of
etelcalcetide in this setting. Blood, dialysate, urine, and feces
were collected to characterize the pharmacokinetics, bio-
transformation product profiles, mass balance, and formation
of anti-etelcalcetide antibodies. Accelerator mass spectrom-
etry was necessary to measure the microtracer quantities of
C-14 excreted in the large volumes of dialysate and other
biomatrices.An estimated 67 %of the [14C]etelcalcetide dose
was recovered in dialysate, urine, and feces 176 days after
dose administration. Etelcalcetide was primarily cleared by
hemodialysis, with approximately 60 % of the administered
dose eliminated in dialysate.Minor excretionwas observed in
urine and feces. Biotransformation resulted from disulfide
exchange with endogenous thiols, and preserved the
etelcalcetide D-amino acid backbone. Drug-related radioac-
tivity circulatedprimarily as serumalbumin peptide conjugate
(SAPC). Following removal of plasma etelcalcetide by
hemodialysis, re-equilibration occurred between SAPC and
L-cysteine present in blood topartially restore the etelcalcetide
plasma concentrations between dialysis sessions. No unan-
ticipated safety signals or anti-etelcalcetide or anti-SAPC
antibodies were detected.
Key Points
Hemodialysis was the predominant clearance and
elimination pathway of etelcalcetide following a
single dose of [14C]etelcalcetide in chronic kidney
disease patients on hemodialysis.
Biotransformation resulted from reversible disulfide
exchange with endogenous thiols, and the
etelcalcetide D-amino acid backbone was preserved.
The majority of circulating etelcalcetide-related
biotransformed moieties existed as serum albumin
peptide conjugate (SAPC).
After removal of plasma etelcalcetide by dialysis, re-
equilibration between SAPC and L-cysteine present
in blood partially restored predialysis concentrations
of etelcalcetide.
1 Introduction
Calcimimetics are a class of drugs that activate the
parathyroid calcium-sensing receptor (CaSR) to inhibit
parathyroid hormone (PTH) secretion [1, 2]. Dysregulation
of CaSR signaling plays an important role in the
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development of secondary hyperparathyroidism (SHPT), a
frequent comorbidity for patients with chronic kidney
disease (CKD) that is characterized by elevated PTH
levels, mineral disturbances, and increased risk of com-
plications and death [1].
Etelcalcetide (AMG 416) (Fig. 1) is a novel intravenous
calcimimetic in clinical development for SHPT treatment.
Etelcalcetide is a 1048 Da synthetic peptide comprising a
linear chain of seven D-amino acids (referred to as the
‘D-amino acid backbone’) and an L-cysteine linked to the
D-cysteine by a disulfide bond. Formation of a covalent
disulfide bond between the D-cysteine of etelcalcetide and
cysteine 482 of the CaSR results in allosteric activation of
the receptor, enhanced signal transduction, and inhibition of
PTH secretion [3]. In two phase III studies in patients with
SHPT on hemodialysis, approximately 75 % of those
administered etelcalcetide achieved a[30 % PTH reduction
from baseline versus 8–10 % of those receiving placebo [4].
Pharmacokinetic profiles of etelcalcetide and
[14C]etelcalcetide-derived radioactivity (referred to as ‘total
C-14’) in rat plasma showed a multiphase decline with a
long terminal half-life (t) [5]. In rats with intact kidneys,
total C-14 following a single intravenous dose was pre-
dominantly excreted in urine (77–84 % of administered
dose; approximately 90 % of recovered dose). In bilaterally
nephrectomized rats, recovery of total C-14 was low and
elimination by nonrenal pathways was slow. Etelcalcetide
biotransformation occurred in whole blood primarily by
disulfide exchange with endogenous thiol-containing
molecules; the D-amino acid backbone was unaltered. The
predominant biotransformation product present in plasma
was a covalently bound serum albumin peptide conjugate
(SAPC) [5].
In clinical studies, the importance of renal clearance was
indicated by a prolonged etelcalcetide t in patients with
CKD on hemodialysis (81.7–175 h) compared with healthy
volunteers (18.4–20.0 h) [6–8]. These findings were con-
sistent with the role of renal clearance determined in rats
[5]. Based on the nonclinical findings that biotransforma-
tion of etelcalcetide only occurs by reversible disulfide
exchange [9], and because renal clearance is the primary
mechanism of elimination in animals and humans with
intact renal function [5, 7], dialytic clearance was expected
to be the main elimination pathway in patients with limited
or no kidney function undergoing hemodialysis. In previous
clinical studies [8, 10, 11], the duration of pharmacokinetic
data collections was limited and the effect of hemodialysis
on the pharmacokinetics of etelcalcetide was unknown.
This study was conducted to elucidate the pharmacoki-
netics, biotransformation, and excretion of etelcalcetide in
patients with CKD on hemodialysis. A therapeutic dose
was administered that contained a microtracer quantity of
[14C]etelcalcetide in order to limit patient exposure to C-14
and to facilitate study conduct in a dialysis clinic. The
microtracer approach necessitated using accelerator mass
spectrometry (AMS) to achieve the sensitivity required for
quantification of the low concentrations of radioactivity
excreted in the large volumes of dialysate and other
biomatrices over the long study duration.
2 Materials and Methods
2.1 Radiolabeled Drug and Formulation
[14C]etelcalcetide drug substance (Fig. 1; hydrochloride
salt; specific activity 70.9 nCi/mg of etelcalcetide freebase;
high-performance liquid chromatography [LC] purity
99.5 %) was synthesized at Amgen Inc. (Thousand Oaks,
CA, USA). The C-14 label was placed on the carbonyl
carbon of the N-acetyl moiety in the D-amino acid back-
bone and the stability of the radiolabel at this position was
demonstrated in nonclinical studies [5]. The drug substance
was formulated as a single 10 mg dose of etelcalcetide
with 26.3 kBq (710 nCi; approximately 10 lg) of
[14C]etelcalcetide in 2 mL liquid solution for bolus intra-
venous administration at the end of hemodialysis. The
formulation was a sterile, preservative-free, aqueous solu-
tion containing 0.85 % sodium chloride, and 10 mM suc-
cinic acid, in a single-use 5 mL type 1 glass vial. The drug
product vial for each patient was prepared at the clinical
site by combining the drug substance in the liquid formu-
lation and contained 4 mL of clear, colorless solution with
AMG 416 concentration of 5 mg/mL at a final pH of 3.3.
2.2 Study Design and Objectives
This phase I, open-label study (Fig. 2) was conducted at a
single center in the US (DaVita Clinical Research, Min-
neapolis, MN, USA) in compliance with the International
Conference on Harmonisation Tripartite Guideline on
Fig. 1 Structure of etelcalcetide. The drug substance was formulated
as a single 10 mg dose of etelcalcetide (with 26.3 kBq of
[14C]etelcalcetide; 10 lg) in 2 mL liquid solution for bolus intra-
venous administration at the end of hemodialysis. The formulation
was a sterile, preservative-free, aqueous solution containing 0.85 %
sodium chloride and 10 mM succinic acid. Ala, Arg, Cys denote the
alanine, arginine, and cysteine amino acids, Ac denotes the acetyl
group on the N-terminus of the D-cysteine, and NH2 denotes
amidation on the C-terminus of the D-arginine. The asterisk denotes
the position of the C-14 radiolabel placed on the carbonyl carbon of
the acetyl moiety
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Good Clinical Practice. Patients provided written informed
consent.
The specific objectives of the study were (i) to deter-
mine the rate, extent, and routes of radioactivity excretion
of [14C]etelcalcetide in feces, dialysate, and urine over
time; and (ii) to measure radioactivity concentrations in
whole blood and plasma over time. Secondary objectives
were to (i) measure etelcalcetide concentrations in plasma
for comparison with total C-14 concentrations; (ii) evaluate
the safety and tolerability of a single intravenous dose
(10 mg) of etelcalcetide; and (iii) assess the effect of
hemodialysis on the pharmacokinetics of etelcalcetide and
total C-14.
2.2.1 Patient Selection
Six patients aged C18 years with stage 5 CKD on
hemodialysis were enrolled in this study. Each patient had
a stable dialysis prescription that was not anticipated to
change significantly during the course of the study; a body
mass index between 18 and 38 kg/m2; corrected calcium
[8.3 mg/dL; and PTH between 300 and 1200 pg/mL.
Patients were excluded if they had received etelcalcetide or
cinacalcet (a small molecule calcimimetic [12]) within
30 days. Patients were also excluded if any [14C]-labeled
drug substance within 1 year to ensure that no residual
drug-related C-14 is present in the samples from these
subjects, which may confound the results obtained through
AMS analysis.
2.2.2 Study Treatment
Patients were resident in the clinical study site for 12 days
(i.e. study day -1 until completion of procedures on study
day 11) and underwent hemodialysis three times per week
for the duration of the study (Fig. 2). The hemodialysis
time was fixed as per the patient prescription and its
duration ranged from 3 to 4 h across the study subjects. All
patients used the same dialyzer model (Optiflux F180NR;
Fresenius Medical Care, Waltham, MA, USA). At the end
of hemodialysis on study day 1, patients received a single
intravenous bolus dose of [14C]etelcalcetide into the arm
opposite the arm used for hemodialysis, followed by a
5 mL saline flush.
2.3 Sample Collection
Blood, dialysate (entire amounts from each hemodialysis
session), urine, feces from each discharge, and vomit from
each emesis were collected (Fig. 2) and processed as
described in the electronic supplementary methods. Blood
samples were also collected from predialyzer and
Fig. 2 Study scheme. Pharmacokinetic sampling was performed
using the patient’s nonhemodialysis arm at predose, 0.17, 1, 4, 8, 24,
48, 68, 72, 72.17, 73, 76, 80, 96, 116, 120, 144, 168, 192, 216, 236,
240, 332, 500, 668, and 908 h postdose. Predialyzer (arterial) and
postdialyzer (venous) blood samples were withdrawn from the
respective hemodialysis lines during dialysis on study day 4 at
approximately 10 min, 2 h (midpoint), and the end of dialysis (range
3–4 h). Pharmacokinetic sampling was performed using the patient’s
nonhemodialysis arm after completion of the hemodialysis session on
study day 4 at 0.17, 1, 4, and 8 h. Additional blood samples were
collected for the extended pharmacokinetic collection period during
study days 129–176. Serum for anti-etelcalcetide antibody analysis
was collected on study days -1 and 39. Total dialysate was collected
for each patient during the in-clinic period (study days 1–11) and on
outpatient study days 14–39; a proportion of each patient’s total
dialysate was combined, and the pooled dialysate stored at -70 C
for C-14 analysis and biotransformation product profiling. Predose
and postdose urine were collected if discharged on study days 1–11 in
24 h intervals, pooled, and stored at -70 C for C-14 analysis and
biotransformation product profiling. Predose and postdose feces were
collected on study days 1–11, frozen at -70 C, shipped to Covance
Laboratories (Madison, WI, USA), combined by patient at 24 h
intervals, and homogenized in ethanol/water (1:1 v/v); a portion was
lyophilized and stored at room temperature for C-14 analysis, and a
portion was stored at -70 C for biotransformation product profiling.
aAdditional extended pharmacokinetic collection period (study days
129–176)
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postdialyzer (arterial and venous) lines during the
hemodialysis session on study day 4 and after completion
of hemodialysis. After the in-clinic period, patients
returned to the site on an outpatient basis in accordance
with their routine hemodialysis sessions up to study day 39.
Four patients returned for two extended collection periods,
each comprising three consecutive hemodialysis sessions
(collection period 1: study days 129–148; collection period
2: approximately 1 month after collection period 1, corre-
sponding to study days 157–176). Blood and dialysate were
collected during each outpatient day visit. Blood samples
were collected into potassium-EDTA (Fig. 2) for C-14
analysis, etelcalcetide and total M11 (TM11; described in
Sect. 2.4) bioanalysis, and biotransformation product pro-
filing. Blood, dialysate, urine, and feces were collected,
processed, and stored for additional analyses as described
(Fig. 2). Dialyzer cartridges were collected after each
hemodialysis session for each patient. Serum for anti-
etelcalcetide antibody analysis was collected on study days
-1 and 39.
2.4 Bioanalysis of Etelcalcetide and TM11
Plasma concentrations of etelcalcetide and TM11 were
determined by LC–tandem mass spectrometry (MS/MS) as
described in the electronic supplementary methods. TM11
is the sulfhydryl (reduced) form of the D-amino acid pep-
tide backbone in etelcalcetide [5].
2.5 Accelerator Mass Spectrometry Analysis
The C-14 content in whole blood, plasma, dialysate, urine,
and fecal samples was determined by AMS at Xceleron
Inc. (Germantown, MD, USA) following a graphitization
procedure as described in the electronic supplementary
methods.
2.6 Biotransformation Product Profiling
Radioprofiles and biotransformation product identification
were performed on pooled samples of plasma, urine, and
dialysate with and without tris(2-carboxyethyl phosphine)
(TCEP) reduction as described in the electronic supple-
mentary methods. Structure assignments of etelcalcetide
and its biotransformation products were based on com-
parisons to known structures from nonclinical studies [5],
authentic standards, calculations, and interpretations from
high-resolution MS and LC–MS/MS data.
2.7 Pharmacokinetic Analysis
All patients who received a single dose of etelcalcetide
were included in the pharmacokinetic analysis set.
Noncompartmental analyses were performed on individual
plasma etelcalcetide, plasma C-14, and plasma TM11
concentration–time data from samples taken from the
patient’s nonhemodialysis arm during the nonhemodialysis
period using Phoenix WinNonlin v.6.3 software on Citrix
(Pharsight, St. Louis, MO, USA). Mean (standard devia-
tion) concentration–time profiles were generated using
Phoenix WinNonlin v.6.3 (Pharsight), as were all
descriptive statistics. Pharmacokinetic parameters (e.g.
maximum observed drug concentration [Cmax], time to
reach Cmax [tmax], area under the plasma concentration–
time curve [AUC], hemodialysis clearance [CLHD], and
extraction ratio [EHD]) were estimated as described in the
electronic supplementary methods.
2.8 Estimation of Carbon-14 Excretion
on Nonsampled Days
The total C-14 recovery in dialysate over the period
between day 39 and the start of the extended collection
period was estimated by interpolation. The total C-14
excretion rate on nonsampled days was estimated with the
assumption that the dialysis excretion rate was a first-order
process (electronic supplementary Fig. 1). A straight line
(Y = slopeX ? intercept) regression was applied to the
log-transformed excretion rate (Y) versus time (X) profile.
Regression analysis was applied for the measured data from
study day 27 to the last time point; these correspond to six
time points from study days 27 to 39, and six time points in
the two extended pharmacokinetic collection periods.
The cumulative total C-14 excretion in urine and feces
on nonsampled days (study days 11–176) was estimated for
each patient by extrapolation using the following
equations:
CEU;SD11 to SD176 ¼ CEU;SD1 to SD10
CED;SD4 to SD11
 
 CED;SD14 to SD176
CEF;SD11 to SD176 ¼ CEF;SD1 to SD10
CED;SD4 to SD11
 
 CED;SD14 to SD176
where CE is the cumulative excretion in respective matri-
ces (U = urine, F = feces, D = dialysate), and SD is
study day.
2.9 Safety Analysis
All patients in the study were included in the safety anal-
ysis set. Adverse events were classified according to the
Medical Dictionary for Regulatory Activities version 17.0
[13], and graded according to the Common Terminology
Criteria for Adverse Events version 4.0 [14]. Adverse
events were reported through study day 39 or the last visit
of the extended pharmacokinetic collection period.
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2.10 Anti-Etelcalcetide Antibody Analysis
A validated biosensor immunoassay was used to screen for
and confirm the presence of binding anti-etelcalcetide and
anti-SAPC antibodies (electronic supplementary methods).
3 Results
3.1 Pharmacokinetic Analyses
Demographics of the six subjects are provided in Table 1.
Mean concentration–time profiles of total C-14 in blood
and plasma, etelcalcetide, and TM11 (in plasma) after a
single intravenous bolus administration of [14C]etelcalcetide
(10 mg; 26.3 kBq) to patients with CKD on hemodialysis
are shown in Figs. 3a, b and 4. Etelcalcetide concentrations
in plasma decreased during hemodialysis and rebounded
slowly after the end of hemodialysis (Fig. 3a). Total C-14
concentration in blood was lower than that in plasma over
the time course (Fig. 3a). Mean blood to plasma radioac-
tivity concentration ratio was 0.6, indicating limited dis-
tribution of radioactivity into blood cells. Pharmacokinetic
parameters during the nonhemodialysis period for total
C-14, etelcalcetide, and TM11 in plasma are shown in
Table 2.
Estimates of pharmacokinetic parameters during
hemodialysis are summarized in Table 3. Arterial and
venous plasma etelcalcetide concentrations were deter-
mined and used to calculate EHD and CLHD for etelcalcetide
(mean EHD 0.385; CLHD 7660 mL/h). Total C-14 in blood
and plasma, etelcalcetide in plasma, and TM11 in plasma
from the predialyzer arterial line were greater than the
corresponding concentrations in the postdialyzer venous
line (Fig. 4). Changes in the arterial and venous concen-
trations of blood and plasma total C-14 and plasma TM11
were too small to determine their EHD and CLHD.
Etelcalcetide concentrations in plasma were lower than
the corresponding concentration of total C-14 in plasma,
indicating the presence of circulating biotransformation
products (Fig. 3a, b). TM11 concentrations in plasma were
similar to the concentrations of total C-14 in plasma. A
regression analysis of the pooled data in which TM11 and
total C-14 concentrations were available for a given time
point across all patients demonstrated a goodness of fit (R2)






Median age, years (range) 62 (33–75)
Race, n (%)
Black (or African American) 5 (83.3)
White 1 (16.7)
Median height (range), cm 171.9 (162–184)
Median weight (range), kg 91.3 (51.7–120.5)
Median body mass index (range), kg/m2 32.3 (19.7–35.6)
b
a
Fig. 3 Mean (SD) concentration versus nominal time profiles of total
C-14 in blood and plasma, etelcalcetide in plasma, and TM11 in
plasma following a single intravenous bolus administration of
[14C]etelcalcetide (10 mg; 26.3 kBq) to patients with CKD on
hemodialysis (during nonhemodialysis periods). a Predose to 10 days
postdose (study days 1–11). b Predose to 175 days postdose (study
days 1–39 and 129–176). Each pair of vertical dashed lines represents
a hemodialysis period. C-14 [14C]etelcalcetide-derived radioactivity,
CKD chronic kidney disease, SD standard deviation, TM11 total M11
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value of 0.97. Plasma AUC ratios between TM11 and total
C-14 were also close to unity (Table 2), indicating that all
[14C]-labeled components were quantitatively converted to
TM11 by chemical reduction; therefore, the D-amino acid
backbone in etelcalcetide was predominantly intact in the
C-14 products present in plasma.
3.2 Excretion
The estimated overall mean recovery, the mean sum of
measured recovery on sampled days and estimated recov-
ery on nonsampled days (Sect. 2.8), of radioactivity was
67.2 % after 175 days (Table 4). Hemodialysis was the
Fig. 4 Mean (SD)
concentration versus nominal
time profiles of total C-14 in
plasma, and etelcalcetide in
plasma during the first
hemodialysis period postdose




26.3 kBq) to patients with CKD
on hemodialysis. Vertical







Table 2 Summary of pharmacokinetic parameters during the nonhemodialysis period for analytes total C-14, etelcalcetide, and total M11 in
plasma after a single intravenous bolus administration of [14C] etelcalcetide (10 mg; 26.3 kBq) in patients with CKD on hemodialysis
Total C-14 Etelcalcetide Total M11
n Mean (SD) CV% n Mean (SD) CV% n Mean (SD) CV%
tmax,
minutea
6 10 (10–12) NR 6 10 (10–11) NR 6 10 (10–60) NR
Cmax
b 6 697 (207) 29.7 6 347 (69.5) 20.0 6 705 (172) 24.4
tlast, day
a 6 164 (37.6–174) NR 6 37.8 (37.6–145) NR 6 13.8 (9.8–20.7) NR
Clast
a,b 6 3.01 (2.06–24.7) NR 6 2.50 (0.210–2.80) NR 6 57.9 (50.8–62.7) NR
t,z, day 4 35.9 (2.99) 8.3 2 NR (NR) NR 0 NR (NR) NR
AUC3d
b 6 585 (98.8) 16.9 6 81.6 (8.4) 10.3 6 590 (101) 17.1
AUC10d
b 6 1220 (172) 14.1 6 160 (16.9) 10.6 6 1150 (190) 16.4
Ratio to 14C
AUC3d NR NR (NR) NR 6 0.142 (0.0219) 15.4 6 1.01 (0.124) 12.2
AUC10d NR NR (NR) NR 6 0.132 (0.0151) 11.5 6 0.947 (0.0973) 10.3
Values were rounded to three significant figures, except for CV% and tmax, which are reported to one decimal place and two significant figures,
respectively
AUC area under the plasma concentration–time curve, AUC3d AUC from time zero to 3 days (68 h) postdose, AUC10d AUC from time zero to
10 days (240 h) postdose, CKD chronic kidney disease, Clast last observed plasma concentration, Cmax maximum observed drug concentra-
tion, CV coefficient of variation, NR not reported, SD standard deviation, tlast time Clast was observed, tmax time to reach Cmax, total C-14
[14C]etelcalcetide-derived radioactivity, t,z apparent terminal half-life
a Median (range) values are provided for tmax, tlast, and Clast
b The total C-14 parameter values are reported in ng-eq/mL (Cmax and Clast) and dayng-eq/mL (AUC3d and AUC10d), whereas plasma
etelcalcetide parameter values are reported in ng/mL (Cmax and Clast) and dayng/mL (AUC3d and AUC10d)
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predominant elimination pathway (Table 4; Fig. 5); an
estimated mean of 59.6 % of the administered dose
(88.7 % of recovered dose) was eliminated in dialysate.
The mean total C-14 elimination t was similar for dia-
lysate (40.2 days) and plasma (35.9 days). A small pro-
portion of the dose was excreted in urine (3.2 % of
administered dose) and feces (4.5 % of administered dose).
Radioactivity was below the lower limit of quantification in
the sole vomit sample. Etelcalcetide and its biotransfor-
mation products did not bind to an appreciable extent to the
dialyzer membrane and cartridge. Only trace levels of
radioactivity (0.005 % of administered dose) were recov-
ered in extracts from the dialyzer used in the first dialysis
session; thus, dialyzers were not further analyzed.
3.3 Biotransformation
Radiochromatograms of pooled plasma, urine, and dialy-
sate samples are shown in Fig. 6 and electronic supple-
mentary Fig. 2, while radiochromatograms of TCEP-
treated plasma, urine, and dialysate samples are shown in
electronic supplementary Fig. 3. MS and MS/MS frag-
mentation data for etelcalcetide and its biotransformation
products are presented in Table 5 and were used to develop
the etelcalcetide biotransformation scheme shown in
Fig. 7.
In plasma, nearly all of the C-14 chromatogram peaks
(Fig. 6a; Table 6) were identifiable in the LC-high-
resolution mass spectrometry (HRMS) profile (Table 5).
Etelcalcetide biotransformation resulted predominantly
from disulfide exchange. In plasma from the first interdi-
alytic period after dosing (AUC68hr), intact etelcalcetide
accounted for approximately 17 % of the total C-14 AUC3d
after dose administration and before the first postdose
dialysis session. Covalent protein conjugates, presumed to
be SAPC based on nonclinical characterization [5], were
the most abundant biotransformation product in plasma
(73 % of the total radioactivity in the pooled plasma)
(Table 6). SAPC formation in plasma was confirmed by
LC-HRMS analysis of the Lys-C digest of SAPC. Other
biotransformation products were each \4 % of the total
C-14 AUC68hr. In plasma from the second interdialytic
period (AUC72–116h) (Fig. 6b), intact etelcalcetide
accounted for approximately 13 % of the total C-14 AUC;
covalent protein conjugates were the most abundant bio-
transformation product in plasma (83 % of the total
radioactivity); other biotransformation products were
each\2 % of the total C-14 AUC72–116h. No desacetylated
biotransformation product or the corresponding reduced
form, both leading to loss of the radiolabel, was observed
in plasma or TCEP-reduced plasma. TCEP reduction of the
plasma resulted in formation of, predominantly, a single
TM11 peak (84 %) (Table 7).
In dialysate (Fig. 6c), the biotransformation product
profile consisted of all components observed in plasma,
except the protein conjugates. TCEP reduction of the dia-
lysate resulted in a major TM11 peak (77.8 %) and a minor
amount of reduced M5 (1.1 %) (Table 7). Several
Table 3 Summary of pharmacokinetic parameter values during
hemodialysis for etelcalcetide in arterial and venous plasma after a
single intravenous bolus administration of [14C]etelcalcetide (10 mg;
26.3 kBq) in patients with CKD during the first hemodialysis period
postdose on study day 4
Analyte etelcalcetide [N = 6]
Mean (SD) CV%
AUCA,HD, ngday/mL 1.79 (0.467) 26.1
AUCV,HD, ngday/mL 1.09 (0.264) 24.2
EHD 0.385 (0.0679) 17.6
QB, mL/min 533 (51.6) 9.7
HCT 37.3 (5.33) 14.3
QP, mL/min 333 (31.3) 9.4
CLHD, mL/h 7660 (1380) 18.0
Values were rounded to three significant figures, except for CV%,
which is reported to one decimal place
AUCA,HD area under the arterial plasma concentration–time curve
obtained during the hemodialysis session on study day 4, AUCV,HD
area under the venous plasma concentration–time curve obtained
during the hemodialysis session on study day 4, CKD chronic kidney
disease, CLHD hemodialysis clearance, CV coefficient of variation,
EHD hemodialysis extraction ratio, HCT hematocrit; QB blood flow
rate through the dialyzer during hemodialysis, QP plasma flow rate
through the dialyzer during hemodialysis, SD standard deviation
Table 4 Cumulative excretion of radioactivity following adminis-
tration of a single intravenous dose of [14C]etelcalcetide (10 mg;
26.3 kBq) in patients with CKD on hemodialysis
Estimated cumulative recovery from












CKD chronic kidney disease, SD standard deviation
a Mean and SD values computed with values from four patients who
completed the extended pharmacokinetic collection period




Fig. 5 Cumulative recovery of
radioactivity following
administration of a single
intravenous dose of
[14C]etelcalcetide (10 mg;
26.3 kBq) to patients with CKD
on hemodialysis (n = 6).
Excretion in a dialysate;
b urine; and c feces. CKD
chronic kidney disease, PK
pharmacokinetic
Fig. 6 HPLC
radiochromatogram of a AUC
pooled plasma (0–68 h); b AUC
pooled plasma (approximately
72–116 h); c pooled dialysate
from the first hemodialysis
session following a single
intravenous dose of
[14C]etelcalcetide (10 mg;
26.3 kBq) to patients with CKD
on hemodialysis. AUC area
under the plasma concentration–
time curve, CKD chronic kidney
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Table 5 Summary of representative LC-HRMS data for etelcalcetide and its biotransformation products
Component RT (min) Calculated m/z (2?)e Observed m/z (2?)e Difference (ppm) Product ion data
Etelcalcetidea 12.40 524.7718 524.7707 -2.1 448, 464, 481
SAPCb 35.14 672.7604 672.7707 -15.3 299, 448, 714, 742, 770, 795
M1a 16.62 505.2482 505.2482 0 448, 464
M2aa 26.28 NA 617.2879 NA 448, 465, 481
M2ba 27.74 NA 617.2866 NA 448, 465, 481
M3a 28.02 638.8091 638.8088 -0.5 448, 465, 481
M4a 29.69 574.7798 574.7802 0.7 448, 464, 481, 524
M5a 13.58 525.2638 525.2630 -1.5 448, 464, 481
M7a 18.71 698.8303 698.8295 -1.1 448, 464, 481, 617
M9a 22.85 NA 560.7634 NA 448, 464, 481
M10c 20.45 617.8038 617.8073 5.7 448, 465, 481
M11d 20.41 465.2698 465.2716 3.9 448
M13a 16.29 553.2826 553.2825 -0.2 448, 464
M14a 18.18 531.7796 531.7789 -1.3 448, 465
M15c 19.47 589.2931 589.2968 6.3 448, 464, 481, 524
M28a 14.64 489.2621 489.2620 -0.2 NA
M29a 27.59 545.7771 545.7767 -0.7 448, 464, 481
NA not available, LC liquid chromatography, HRMS high-resolution mass spectrometry, m/z mass-to-charge ratio, ppm parts per million, RT
retention time, SAPC serum albumin peptide conjugate, TCEP tris(2-carboxyethyl phosphine)
a From human urine data
b From Lys-C digest of SAPC
c From human dialysate data
d From TCEP-treated human urine data
e Charge state of the precursor molecular ion except the m/z for SAPC peptide was from a 5? charge state
Fig. 7 Proposed biotransformation scheme for [14C]etelcalcetide in
humans. Lower and upper case single-letter amino acid abbreviations
refer to D- and L-amino acids, respectively. G L-glutathione, minor
each\5 % of C-14 dose (urine) or C-14 chromatogram (plasma), m/
z mass-to-charge ratio. aThe structure was confirmed by an authentic
standard. bThe structure has an intact peptide backbone but the exact
modification could not be determined. The observed doubly charged
m/z of 12C-precursor for M2a and M2b and M9 were 617.2879,
617.2866, and 560.7634, respectively. The mass shifts for these
products were 185.0322, 185.0296, and 71.9832 Da, respectively.
These values were not available for unknowns 1, 2, and 3
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Table 6 Summary of biotransformation product profile in plasma, dialysate, and urine following intravenous administration of [14C]etelcal-
cetide (10 mg; 26.3 kBq) in patients with CKD on hemodialysis
% C-14 Chromatogramc
Name Proposed Structure Plasmad Dialysatee Urinef
Etelcalcetide L-cysteine disulfide 17.4 48.0 22.3






M2a m/z 617.28b ND ND 4.1
M2ba m/z 617.28b ND ND
2.5
M29a Acetylated etelcalcetide ND g





M5 Des-amido etelcalcetide ND 0.4 1.8
M7a













M9 m/z 560.76b ND g 3.4
M10 L-glutathione disulfide 0.5 2.1 ND
M28 Thiosulfate ND 0.8 1.1
Protein 
conjugates
SAPCg 72.9 ND ND
Unk1 NA ND ND 6.9
Unk2 NA ND ND 1.6
Unk3 NA ND ND 28.6
CKD chronic kidney disease, m/z mass-to-charge ratio, NA not applicable, ND not detected, SAPC serum albumin peptide conjugate, Unk1,
Unk2, Unk3 unknown peaks
a Biotransformation products were co-eluted
b The precursor ion was detected by mass spectrometry; D-amino acid back bone was intact, but the structure could not be determined
c % C-14 chromatogram = peak area of etelcalcetide or its biotransformation product divided by the total peak area of all etelcalcetide-related
components
d AUC68h pool (see sample pooling in electronic supplementary methods). Each unidentified component was\4 % in C-14 chromatogram
e Day 4 pool (see sample pooling in electronic supplementary methods). Each unidentified component was\7 % in C-14 chromatogram
f Day 1–10 pool (see sample pooling in electronic supplementary methods). Each unidentified component was\3 % in C-14 chromatogram
g Peak characterized by liquid chromatography/high-resolution mass spectrometry analysis. SAPC was inferred to be the predominant com-
ponent in the protein conjugates based on in vitro characterization
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unidentified peaks were observed in the pooled day 4
dialysate before and after TCEP, each individually\7 and
\5 %, respectively. No desacetylated biotransformation
product or the corresponding reduced form was observed in
dialysate or TCEP-reduced dialysate. In urine, the most
abundant component was intact etelcalcetide (approxi-
mately 25 % of the 14C-chromatogram). In addition to
etelcalcetide, 12 known biotransformation products were
detected in urine (electronic supplementary Fig. 2). Peaks
from unidentified components were each\1 % of the
administered dose. TCEP reduction of the urine resulted in
formation of, predominantly, a single TM11 peak (67.4 %)
(Table 7). Several unidentified peaks were observed in the
TCEP-reduced urine, each individually\5 % of the 14C-
chromatogram. No desacetylated biotransformation pro-
duct or its reduced form was observed in urine or TCEP-
reduced urine. Feces were not profiled for biotransforma-
tion products because of the low amount of fecally excreted
radioactivity. Cumulative excretion ratios in urine and
feces on nonsampled days were estimated for each patient
(electronic supplementary Table 1).
3.4 Safety
Treatment-emergent adverse events occurred in five
patients and included constipation (n = 2), contact der-
matitis, flatulence, nausea, pneumonia, upper respiratory
tract infection, and vomiting (each n = 1); events were mild
in intensity, with the exception of one serious adverse event
of severe pneumonia. Of these, only constipation and flat-
ulence were considered treatment-emergent adverse events.
3.5 Anti-Etelcalcetide Antibodies
No antibodies against either etelcalcetide or SAPC were
detected in six predose and six postdose (study day 39)
samples.
4 Discussion
Etelcalcetide is a novel synthetic peptide composed almost
entirely of D-amino acids. Minimal literature is available on
the human disposition of peptides predominantly composed
of D-amino acids, since there is no approved drug in this
chemical class. The objective of this study was to charac-
terize the pharmacokinetics, biotransformation, and
excretion following a single microtracer intravenous dose
of [14C]etelcalcetide to patients with CKD on hemodialy-
sis. Higher quantities of C-14 more typical for human drug
disposition studies were considered but not pursued
because of the difficulty in controlling radioactivity con-
tamination if hospitalizations were required during the
study. One patient required hospitalization, and microtracer
labeling obviated the need for contamination controls. The
microtracer approach required the use of AMS for C-14
measurement in biofluids and dialysate. Remarkable
detection limits were enabled by AMS, with C-14 con-
centrations of approximately 0.25 mBq (approximately
6.7 fCi/g) of 14C (approximately 0.06 ng equivalents of
etelcalcetide/g) quantified in an approximately 0.35 g dia-
lysate sample prepared from approximately 150 kg of
dialysate collected on study day 176.
Nonclinical investigations indicated that etelcalcetide
and its biotransformation products exist in a dynamic
equilibrium in blood [9]. Etelcalcetide undergoes bio-
transformation to form conjugates by disulfide exchange
with endogenous thiols present in blood [5, 9]. These
products were previously observed in vitro (human and rat)
and in vivo (rat) [5]. In rats, a majority of etelcalcetide-
related moieties in circulation existed in the form of
covalent protein conjugates inferred to be SAPC. SAPC
was characterized in plasma following in vitro incubations
of etelcalcetide in whole blood; it was demonstrated to be a
disulfide conjugation of the etelcalcetide D-amino acid
backbone to the L-cysteine 34 of serum albumin [5].
Table 7 Summary of biotransformation product profile in TCEP-treated plasma, dialysate, and urine following intravenous administration of
[14C]etelcalcetide (10 mg; 26.3 kBq) in patients with CKD on hemodialysis
Name Proposed structure % C-14 chromatograma
Plasmab Dialysateb Urineb
TM11 Sulfhydryl (reduced form) of etelcalcetide backbone 83.8 77.8 67.4
M5-DesCys Des-amido M11 1.4 1.1 3.2
CKD chronic kidney disease, TCEP tris(2-carboxyethyl phosphine)
a % C-14 chromatogram = peak area of the etelcalcetide or its biotransformation product divided by the total peak area of all drug-related
components
b Each unidentified component was\5 % in C-14 chromatogram
PK and Disposition of Etelcalcetide in Patients with CKD on Hemodialysis 189
In vitro kinetic studies showed that under the conditions
tested, the rate of etelcalcetide CLHD was[16-fold faster
than its rate of conversion to SAPC, and the rate of con-
version of SAPC to etelcalcetide was approximately
200-fold slower than the dialytic rate constant [9]. Re-
equilibration to form etelcalcetide from SAPC occurred at
a slow rate compared with etelcalcetide elimination by
dialysis [9]. Formation of etelcalcetide from SAPC is
possible because of abundant quantities of L-cysteine pre-
sent in plasma [13].
Based on the nonclinical findings, we hypothesized that
etelcalcetide biotransformation in humans would predom-
inately result from disulfide exchange [5]. Moreover, with
a dialyzer molecular weight cutoff of 10 kDa, we
hypothesized that in patients with CKD on hemodialysis
the drug-related species that would be eliminated during
dialysis would be parent etelcalcetide and low-molecular-
weight biotransformation products. Little change in total
C-14 was expected during dialysis due to restricted dialysis
of SAPC and the slow rate at which SAPC converts back to
etelcalcetide or to any other low-molecular-weight prod-
ucts. Finally, we anticipated that upon cessation of dialysis,
re-equilibration would occur and partially restore plasma
etelcalcetide concentrations. To test these hypotheses,
drug-derived products in plasma and dialysate were char-
acterized and the pharmacokinetics of total C-14 and
etelcalcetide in blood and plasma were determined. In
addition, the dialyzer input and output blood was sampled
during the first dialysis session, and intensive blood sam-
pling was conducted after dialysis cessation.
The shape of the pharmacokinetic profiles of etelcalcetide
and total C-14 were similar. The concentration–time
courses of plasma etelcalcetide and SAPC (inferred from
the total C-14 pharmacokinetic profile) outside the
hemodialysis periods paralleled each other. In general, the
SAPC concentration was approximately fivefold higher
than the etelcalcetide concentration. The etelcalcetide to
SAPC ratio decreased during the hemodialysis session
when etelcalcetide and other low-molecular-weight bio-
transformation products were cleared. After dialysis, a
partial restoration of circulating etelcalcetide concentra-
tions in plasma occurred (Fig. 6b). These observations
were consistent with the hypothesis that most of the radi-
olabeled, etelcalcetide-related species maintain a state of
dynamic equilibrium with etelcalcetide, and that re-equi-
libration occurs following dialytic removal of etelcalcetide.
This was further corroborated by direct determination of
etelcalcetide and total C-14 clearance by dialysis, as
measured by their respective concentrations entering and
exiting the dialyzer during hemodialysis (Fig. 4). Only a
small proportion (approximately 5 %) of the total C-14 that
entered the dialyzer was removed. The nonclinical char-
acterization of SAPC [5], the partial characterization of
SAPC in these patients with CKD, and the near quantitative
conversion of total C-14 to TM11 in plasma, are all con-
sistent with a presumption that most of the total C-14
present in blood was in the form of SAPC. Accordingly,
little removal of total C-14 occurred because SAPC has a
molecular weight of approximately 67 kDa, which is well
above the dialyzer cutoff and thus prevented its removal. In
contrast to limited removal of total C-14, approximately
50 % of the etelcalcetide that entered the dialyzer was
removed, which was consistent with the proportion of
unbound etelcalcetide in plasma. Etelcalcetide noncovalent
binding to plasma proteins (fraction unbound) in patients
with CKD was 0.59 [5]. These findings and the equilibrium
that exists are consistent with the high volume of distri-
bution for etelcalcetide reported in a previous population
pharmacokinetic analysis [10], which can be attributed in
part to reversible disulfide exchange of the etelcalcetide D-
amino acid backbone between all available endogenous
thiols and the L-cysteine readily available in plasma.
Recovery of total C-14 was estimated to be 67 % at
study termination (day 176). The recovery is an estimate
because the dose excreted in dialysate had to be partially
interpolated. In the later part of the study, patients were
released from the clinic and received some hemodialyses in
settings where radioactivity was not quantified. The
majority of the radioactivity was directly quantified. The
predominant clearance pathway of total C-14 was
hemodialysis, with the balance recovered in urine and
feces. The parent drug was the predominant species pre-
sent in dialysate and urine. Approximately 60 % of the
[14C]etelcalcetide dose (approximately 89 % of total C-14
eliminated) was removed by dialysis as the parent drug.
The radiolabeled species in feces was not determined
because of the relatively small quantities of total C-14
present. The lack of higher recovery is likely due to the
long C-14 elimination half-life in patients with stage 5
CKD. Extension of the study to increase recovery of the
C-14 dose was not feasible. The recovery of thiol-
containing drugs in disposition studies is generally low
[15], particularly in patients undergoing hemodialysis for
thiol-containing drugs normally cleared in the urine. For
example, recovery of captopril, an angiotensin-converting
enzyme inhibitor, was inversely proportional to the stage of
renal impairment [16]. Compliance with sample collection
in this study was high; only two dialyses were missed in
one patient due to hospitalization. Loss of C-14 as carbon
dioxide was unlikely because there was no evidence of
acetyl moiety loss in any etelcalcetide biotransformation
products, and\0.2 % of an [acetyl-14C]etelcalcetide dose
in rats was recovered in expired air [5].
Previous in vitro assessments demonstrated that
etelcalcetide was unlikely to be metabolized by cyto-
chromes P450 (CYP450) or peptidases, or subject to
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excretion by transporters [5]. The biotransformation prod-
ucts detected in this study confirmed etelcalcetide was not
metabolized by CYP450 or peptidases, little or no direct
excretion of the drug occurred, and biotransformation
occurred by disulfide exchange.
No unanticipated safety events were detected in this
study. Antibody formation has the potential to alter the
exposure and safety profile of therapeutics with a molec-
ular weight\10 kDa [17, 18]. No anti-etelcalcetide anti-
bodies were detected in serum using an assay designed to
detect etelcalcetide or SAPC-reactive antibodies.
5 Conclusions
The current study provided insight into the complex
pharmacokinetics of etelcalcetide that was not available
from previous clinical studies. The majority of radioac-
tivity (67 %) that was eliminated from a single dose of
[14C]-labeled etelcalcetide 176 days after administration
was removed by hemodialysis. Biotransformation was by
disulfide exchange with endogenous thiols, and no alter-
ation of the D-amino acid backbone was detected. Most of
the circulating etelcalcetide-related biotransformed moieties
existed as SAPC. After removal of plasma etelcalcetide
by hemodialysis, re-equilibration between SAPC and
L-cysteine in blood resulted in partial restoration of etel-
calcetide plasma concentrations between hemodialysis
sessions.
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